Clinical trials · New York, NY
Glioblastoma, IDH-wildtype clinical trials in New York
We’re tracking 7 recruiting glioblastoma, idh-wildtype studies with a site in or near New York — including Phase 1, Phase 1/Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near New York
- NCT07223034RecruitingPhase 1
A study of targeted radiation for PSMA-positive gliomas
This early-phase trial tests a radioactive drug called 177Lu-PSMA-617 for people with certain types of brain tumors (gliomas) that have a specific marker (PSMA). The drug targets and delivers radiation to the tumor cells. It may be an option if standard treatments have been completed.
New York, New YorkAges 18 years+ - NCT05765812RecruitingPhase 1/Phase 2
Debio 0123 with temozolomide for recurrent or new glioblastoma
This early-phase study tests Debio 0123 (an anticancer medicine) combined with temozolomide, and for newly diagnosed patients also with radiation. It aims to see whether this treatment combination can slow or control glioblastoma in adults.
New York, New YorkAges 18 years+ - NCT05879367RecruitingPhase 1
Eflornithine plus temozolomide for newly diagnosed brain cancer
This Phase 1 trial studies whether adding eflornithine to temozolomide (chemotherapy) is safe and potentially helpful for people with newly diagnosed glioblastoma or certain astrocytomas after radiation. It aims to find a workable treatment approach by closely monitoring side effects and early tumor responses.
New York, New YorkAges 18 years+ - NCT07089641RecruitingPhase 1
Testing a new pill for EGFR-mutated glioblastoma
This trial tests a new pill called ERAS-801 for people with a type of brain tumor (glioblastoma) that has a specific change in the EGFR gene. The study is for patients whose tumor has come back after treatment, or for those 70 or older who are newly diagnosed.
New York, New YorkAges 18 years+ - NCT06860594RecruitingPhase 1
Triapine plus radiation for recurrent brain tumors
This trial tests whether adding an experimental drug called triapine to a second round of radiation therapy can help treat brain tumors that have come back after initial treatment. It may be a good option for people with recurrent glioblastoma or astrocytoma who meet safety criteria.
New York, New YorkAges 18 years+ - NCT05432804RecruitingPhase 1/Phase 2
Selinexor added to temozolomide for recurring brain glioblastoma
This trial studies whether adding selinexor to the standard chemotherapy temozolomide (with radiation) can better treat glioblastoma that has come back after prior treatment. If you meet specific tumor, health, and lab requirements, the goal is to slow tumor growth or improve symptoms.
New York, New YorkAges 18 years+ - NCT05271240RecruitingPhase 3
Targeted brain-artery drug added to standard treatment for new GBM
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
New York, New YorkAges 18 years+
Hear when a new Glioblastoma, IDH-wildtype trial opens near New York, NY
We’ll email you when one opens near New York, NY — at most once a week, no account needed, unsubscribe anytime.
Glioblastoma, IDH-wildtype trials in other cities
Where these studies are running near New York
Institutions with a site for the recruiting glioblastoma, idh-wildtype studies listed above.
- Memorial Sloan Kettering Cancer Center · 3 studies
- NYU Langone Health · 3 studies
- Columbia University Irving Medical Center · 2 studies
- Columbia University Herbert Irving Comprehensive Cancer Center
- Cooperman Barnabas Medical Center
- Lenox Hill Hospital
- Memorial Sloan Kettering Basking Ridge
- Memorial Sloan Kettering Bergen
What taking part in a glioblastoma, idh-wildtype study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting glioblastoma, idh-wildtype studies in New York.
Common questions
- Are there glioblastoma, idh-wildtype clinical trials near New York?
- Yes. We're currently tracking 7 recruiting glioblastoma, idh-wildtype studies with a site near New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a glioblastoma, idh-wildtype study near New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site near New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a glioblastoma, idh-wildtype trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New glioblastoma, idh-wildtype studies open near New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.